MedPath

Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer

Phase 2
Active, not recruiting
Conditions
Squamous Non Small Cell Lung Cancer
Non Small Cell Lung Cancer
Lung Cancer
Nonsquamous Non Small Cell Lung Cancer
Interventions
Registration Number
NCT04262856
Lead Sponsor
Arcus Biosciences, Inc.
Brief Summary

This randomized phase 2 open-label study will evaluate the safety and efficacy of zimberelimab (AB122) monotherapy, domvanalimab (AB154) in combination with zimberelimab, and domvanalimab in combination with zimberelimab and etrumadenant (AB928) in front-line, PD-L1 positive, metastatic non-small cell lung cancer.

Detailed Description

Not available

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
151
Inclusion Criteria
  • Male or female participants; age ≥ 18 years
  • Histologically confirmed, treatment naive, metastatic squamous or non-squamous NSCLC with documented high PD-L1 expression, with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
  • Must have at least 1 measurable lesion per RECIST v1.1
  • Adequate organ and marrow function
Exclusion Criteria
  • Use of any live vaccines against infectious diseases within 28 days of first dose of investigational medicinal products (IMPs)
  • Any gastrointestinal condition that would preclude the use of oral medications (eg, difficulty swallowing, nausea, vomiting, or malabsorption)
  • History of trauma or major surgery within 28 days prior to the first dose of IMP
  • Concurrent medical condition requiring the use of supra-physiologic doses of corticosteroids (> 10 mg/day of oral prednisone or equivalent) or immunosuppressive medications
  • Positive test results for Hepatitis B surface antigen, Hepatitis C virus antibody with presence of Hepatitis C qualitative RNA or human immunodeficiency virus (HIV-1 and/or HIV-2) antibody at screening
  • Any active autoimmune disease or a documented history of autoimmune disease or syndrome that required systemic treatment in the past 2 years (ie, with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs), except for vitiligo or resolved childhood asthma/atopy.
  • Prior malignancy active within the previous 2 years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix, breast, or prostate cancer

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Arm 3 (domvanalimab, etrumadenant, and zimberelimab combination therapy)ZimberelimabParticipants will receive oral etrumadenant in combination with domvanalimab IV and zimberelimab IV infusion
Arm 3 (domvanalimab, etrumadenant, and zimberelimab combination therapy)DomvanalimabParticipants will receive oral etrumadenant in combination with domvanalimab IV and zimberelimab IV infusion
Arm 2 (domvanalimab and zimberelimab combination therapy)DomvanalimabParticipants will receive domvanalimab IV in combination with zimberelimab IV infusion.
Arm 2 (domvanalimab and zimberelimab combination therapy)ZimberelimabParticipants will receive domvanalimab IV in combination with zimberelimab IV infusion.
Arm 1 (zimberelimab monotherapy)ZimberelimabParticipants will receive zimberelimab as an intravenous (IV) infusion.
Arm 3 (domvanalimab, etrumadenant, and zimberelimab combination therapy)EtrumadenantParticipants will receive oral etrumadenant in combination with domvanalimab IV and zimberelimab IV infusion
Primary Outcome Measures
NameTimeMethod
Objective response rate (ORR)From randomization until the first documentation of disease progression or death from any cause, whichever occurs first (up to approximately 3-5 years)

ORR as assessed by RECIST v1.1

Progression-free survival (PFS)From randomization until the first documentation of disease progression or death from any cause, whichever occurs first (up to approximately 3-5 years)

PFS as assessed by RECIST v1.1

Secondary Outcome Measures
NameTimeMethod
Disease control rate (DCR)From the date of first occurrence of a documented objective response to first documentation of disease progression or death from any cause, whichever occurs first (up to approximately 3-5 years)

DCR as assessed by RECIST v1.1

Overall Survival (OS)From randomization to death from any cause (up to approximately 5 years)

OS as assessed at the time of PFS

Number of Participants with Treatment Emergent Adverse Events (TEAEs)From Screening until up to 90-100 days after the last dose (approximately 5 years)

The number and percentage of participants that experience TEAE

Pharmacokinetics of zimberelimabCollected during all treatment cycles (each cycle is 21 or 28 days), up to 14 days post last dose, 30, 60 and 100 days post last dose (in total, an average of 2 years)

Serum concentration of zimberelimab as determined by validated assays

Pharmacokinetics of domvanalimabCollected during all treatment cycles (each cycle is 21 or 28 days), up to 14 days post last dose, 30, 60 and 100 days post last dose (in total, an average of 2 years)

Serum concentration of domvanalimab as determined by validated assays

Pharmacokinetics of etrumadenantCollected during all treatment cycles (each cycle is 21 or 28 days), up to 14 days post last dose, 30, 60 and 100 days post last dose (in total, an average of 2 years)

Serum concentration of etrumadenant as determined by validated assays

Immunogenicity of zimberelimabCollected during all treatment cycles (each cycle is 21 or 28 days), up to 14 days post last dose, 30, and 100 days post last dose (in total, an average of 2 years).

Percentage of participants who develop treatment-emergent anti-drug antibodies to zimberelimab

Immunogenicity of domvanalimabCollected during all treatment cycles (each cycle is 21 or 28 days), up to 14 days post last dose, 30, and 100 days post last dose (in total, an average of 2 years).

Percentage of participants who develop treatment-emergent anti-drug antibodies to domvanalimab

Duration of response (DoR)From the date of first occurrence of a documented objective response to first documentation of disease progression or death from any cause, whichever occurs first (up to approximately 3-5 years)

DoR as assessed by RECIST v1.1

Trial Locations

Locations (43)

University of Alabama at Birmingham

🇺🇸

Birmingham, Alabama, United States

Innovative Clinical Research Institute (ICRI)

🇺🇸

Whittier, California, United States

Florida Cancer Specialists

🇺🇸

Gainesville, Florida, United States

Florida Cancer Specialists - Panhandle

🇺🇸

Tallahassee, Florida, United States

Florida Cancer Specialists - East

🇺🇸

West Palm Beach, Florida, United States

Baptist Health Lexington

🇺🇸

Lexington, Kentucky, United States

Norton Cancer Institute

🇺🇸

Louisville, Kentucky, United States

Ochsner Clinic Foundation

🇺🇸

New Orleans, Louisiana, United States

The Valley Hospital - Valley Health System - The Robert and Audrey Luckow Pavilion

🇺🇸

Ridgewood, New Jersey, United States

Clinical Research Alliance

🇺🇸

Lake Success, New York, United States

Scroll for more (33 remaining)
University of Alabama at Birmingham
🇺🇸Birmingham, Alabama, United States
© Copyright 2025. All Rights Reserved by MedPath